ABSTRACT We examined the relations between bronchial reactivity, baseline FEV,, and annual decline of height corrected FEV, (A FEV,/ht3) over 7-5 years in 227 men (117 smokers, 71 ex-smokers, and 39 non-smokers). Men with a clinical diagnosis of asthma or receiving bronchodilator treatment were excluded. Bronchial reactivity was determined as the provocation concentration (PC20) of inhaled histamine sufficient to reduce FEV, by 20%; subjects were divided into reactors (PC2, -16 mg/ml) and non-reactors (PC2, >16 mg/ml). Thirty per cent of smokers, 24% of ex-smokers, and 5% of non-smokers were reactors. When smokers who were reactors were compared with non-reactors, the reactors showed a lower baseline FEV, as percentage predicted in 1981-2 (85% v 108%), and a faster AFEV,/ht3 (14.1 v 9-2 ml/y/m3). Baseline FEV, correlated with PC20 in both smokers (rs = 0-51) and ex-smokers (r, = 0.61), and all 15 subjects with an FEV, under 80% of the predicted value were reactors. In ex-smokers AFEV,/ht3 was similar in reactors and non-reactors (m 9-0 v 7-4 mL/y/m3), despite significant differences in baseline FEV,. When analysis was confined to men with a baseline FEV, over 80% predicted, the prevalence of reactors was significantly increased among smokers and slightly increased among ex-smokers compared with non-smokers, though the mean FEV, was higher in the non-smokers. Bronchial reactivity was not increased in smokers aged 35 years or less. In smokers AFEV,/ht3 was faster in those with a personal history of allergy (usually allergic rhinitis), but was not related to a family history of allergic disease, total serum immunoglobulin E level, absolute blood eosinophil count, or skinprick test score. AFEV,/ht3 was also faster in all subjects taking beta blocker drugs. Thus increased bronchial reactivity was associated with accelerated decline of FEV, in smokers. Although the association could be a consequence of a lower baseline FEV,, a trend towards increased reactivity was found in smokers with normal baseline FEV, and AFEV,/ ht3 was dissociated from increased reactivity in ex-smokers. These findings are compatible with the " Dutch hypothesis," but the association between allergic features and accelerated AFEV,/ht3 was relatively weak, and increased reactivity may follow rather than precede the onset of smoking.
10 contributed little to the development of chronic airflow obstruction in smokers,' more recently we found that smokers with an allergic disposition showed an accelerated rate of decline in lung function. 9 We have therefore extended our studies to a further group of men, who were participating in a different long term follow up of pulmonary function. The prevalence of various allergic features in these men is described elsewhere.'0 In summary, smokers had increased blood eosinophil counts (out of proportion to the increase in total white blood cell counts), while smokers and ex-smokers with negative skinprick test reactions to common allergens had slightly higher serum total immunoglobulin E (IgE) levels than did skintest negative non-smokers. The prevalence of positive skinprick test responses was similar in smokers and non-smokers, although it was greater in ex-smokers. All groups were similar in their personal and family histories of allergic disease. Thus although a few allergic features were associated with smoking habit, most such features appeared to be independent of smoking habit.
In this paper we examine the relationships between bronchial reactivity to histamine, allergic features, smoking habit, and annual decline in spirometric values in these men to obtain evidence for or against the Dutch hypothesis.
Methods
The men studied were originally recruited to a longitudinal study of pulmonary function in 1974" and had been studied at intervals subsequently. Men with a clinical history of asthma, other important chest illness, or an abnormal chest radiograph were excluded in 1974. Since then three of the men (one smoker, one ex-smoker, and one non-smoker) had developed asthma as assessed by the same questionnaire and have been excluded. Seven other subjects who were included in a companion study'0 were excluded from this study because spirometric measurements were incomplete or influenced by irrelevant factors (such as recent abdominal surgery or rib fractures). There remained for study 227 men, comprising 39 non-smokers (never smoked more than one cigarette a day for a year), 117 smokers (almost all of whom smoked cigarettes), and 71 ex-smokers. The mean (SEM) cigarette consumption of the smokers who smoked cigarettes was 23 (1) Taylor, Joyce, Gross, Holland, Pride Bronchial reactivity to inhaled histamine was assessed on the basis of change in forced expiratory volume in one second (FEV,) to measure the response.'2 The subject wore a noseclip and sat in a booth fitted with an extractor fan. Solutions were nebulised by one of two Wright nebulisers of similar output and inhaled via a short mouthpiece during two minutes of normal tidal breathing. The FEV, was recorded on one of two dry bellows spirometers (Vitalograph Ltd), which were checked regularly to establish that their calibration was similar. Results were expressed at BTPS. After baseline spirometry, a control solution of 09% sodium chloride was inhaled and spirometry was repeated; after this doubling concentrations of unbuffered, preservative free histamine acid phosphate were given until either the FEV1 dropped by 20% or the subject inhaled the strongest solution (16 mg/ml) without effect. The initial concentration of histamine used was 2 mg/ml, unless baseline FEV, was less than 80% of the predicted value,'3 when 0-5 mg/ml was used. '4 Reactivity was assessed by measuring the concentration of histamine which provoked a reduction in FEV Table 2 Relation ofhistamine reactvity to smoking history, FEV, and annual AFEV,Iht3
34 81 (704) Ex-smokers (ex-S) 17 53 (75-7) Non-smokers (non-S) 2 (53) 36 
REACTIVITY TO INHALED HISTAMINE
Fifty three of the 223 subjects tested were classed as reactors to histamine, the highest prevalence (30%) being found in smokers; but there were also significantly more reactors among ex-smokers than non-smokers ( Our studies of histamine reactivity were made in the winter, and we were concerned that our results might be influenced by recent upper respiratory infections. Reactivity was not measured in subjects with current symptoms of an upper respiratory infection, but 31% of subjects had had an infection in the previous eight weeks. Reactors were as common, however, among smokers and ex-smokers with recent colds as among those without, and a similar proportion of smokers, ex-smokers, and nonsmokers had had colds. We retested seven subjects who were reactors when originally examinined within eight weeks of a cold after an interval, and all remained reactors to histamine; PC20 values were higher in six and lower in one subject, but the 
Discussion
This study showed that bronchial reactivity to histamine was greater in smokers than in non-smokers and that increased bronchial reactivity was associated with accelerated loss of FEV, in smokers. These findings confirm the findings of previous studies59 and are compatible with the Dutch hypothesis2 3 that bronchial reactivity is increased in smokers with chronic airflow obstruction. In middle aged men, however, there is also a relationship between acclerated annual decline in FEV, and a reduced baseline value of FEV,.' Because reduced baseline airway dimensions may themselves lead to enhanced reactivity,'6 the exaggerated bronchial reactivity we observed in smokers might follow rather than precede acclerated loss of FEV,. We have therefore examined our results to see if they provide evidence on the origins of the increased reactivity in smokers.
The original suggestion of the Dutch workers23 was that smokers with progressive airflow obstruction showed "endogenous" increased bronchial reactivity and atopic features similar to, but less pronounced than, those found in subjects with overt asthma. In this case increased reactivity would antedate the onset of smoking, and allergic features would be associated with accelerated decline of FEV, in smokers. In our study, however, the relation between established markers of allergy and rate of loss of FEV, was relatively weak; of the individual markers examined, only a history of allergic rhinitis was related to an accelerated annual decline of FEV, in smokers. When we compared smokers with rapid and slow annual decline in FEV,, we found that only a family history of allergy was significantly commoner in those with rapid decline. Although other studies have shown some relation between evidence of allergy"9 and accelerated decline of FEV, in smokers, the relevant allergic features have been much less pronounced than is 14 commonly found in asthmatic subjects.
Moreover, we have found'0 increases in certain allergic markers related to the smoking habit itself rather than to the rate of decline in FEV,. Thus positive skinprick test responses were commoner among ex-smokers than among smokers or nonsmokers, the peripheral blood eosinophil count was raised in smokers, and the serum total IgE level was raised in smokers and ex-smokers with negative skin test responses. The size of each increase was again small compared with that seen in asthmatic subjects. The weakness of the association with allergic features raises the possibility that the increased bronchial reactivity in smokers is acquired after smoking is started. Bronchial reactivity was not demonstrably greater in younger smokers than in non-smokers in either this or another recent study of smokers less than 36 years old'7 (which used higher concentrations of histamine). Several other investigations of young symptomless smokers with normal lung function have also failed to detect any consistent difference in bronchial reactivity,'8-2) though one report found slightly diminished reactivity.2' Such studies are open to the criticism that strongly reactive smokers may have already selected themselves out by giving up smoking, leaving only the less reactive smokers for comparison with non-smokers. In a study of baboons this problem was avoided by randomly allocating baboons to smoke or sham smoke for three years, and the baboons who had smoked cigarettes became less reactive to inhaled methacholine.22 Although acute administration of nicotine aerosol blunted the response to methacholine, chronic administration for three months had no additional effect on the baboons' reactivity. 29 The increased bronchial reactivity of smokers therefore appears to be acquired some years after they take up smoking. Several mechanisms have been proposed to explain how prolonged smoking might increase non-specific hyperreactivity. Perhaps the strongest possibility is that increased bronchial reactivity stems from altered geometry of the airways; although PC20 normalises the airway response to the initial baseline FEV,, amplifying factors of altered geometry can considerably exceed this normalisation.'2 16 Our finding that bronchial reactivity was increased in all men with an FEV, below 80% of the predicted value (whether current smokers or ex-smokers) emphasises the important role of altered airway geometry. Indeed, it is rare for diminished airway calibre, however caused, not to be accompanied by exaggerated bronchial reactivity.24 25 When we confined our comparison to men with FEV, above 80% of predicted values,'3 reactors (PC20 -16 mg/ml) to histamine were comTaylor, Joyce, Gross, Holland, Pride moner in smokers than non-smokers but mean FEV, was lower in the smokers, so geometric influences might still be important. In non-reactors (PC20 > 16 mg/ml), the percentage reduction in FEV, after inhalation of the highest concentration of histamine (16 mg/ml) was larger in smokers than in non-smokers, but the degree of reduction was related to baseline FEV,, which was lower in the smokers. Hence even within the conventional normal range of FEV, (and we used reference values'3 which are lower than those of most other studies26) some effect of initial geometry cannot be excluded. Nevertheless, altered geometry is not the only factor in increased reactivity. For a given reduction in baseline FEV, the PC20 in asthmatic subjects reported by others'2 is lower than in our smokers and ex-smokers; similarly, at any given level of baseline airways resistance, subjects with asthma show larger responses to histamine than smokers with chronic airflow obstruction.27 Further, while asthmatic subjects show a close correlation between PC20 for histamine (or methacholine) and the degree of bronchoconstriction induced by hyperventilation,'4 smokers with enhanced reactivity to drugs do not develop bronchoconstriction with hyperventilation,28 29 despite achieving respiratory heat loss sufficient to produce a response in asthmatic subjects with similar PC20.29 Finally, in contrast to the results in young adult smokers, studies of middle aged smokers with completely normal baseline lung function (but often with chronic cough) have shown greater bronchial reactivity to histamine (assessed by changes in airways conductance30) and methacholine (assessed by FEV13' and partial expiratory flow volume curves32) than non-smokers. As the most reactive smokers would presumably have developed some impairment of lung function by middle age and so have been excluded from the study, these results suggest that enhanced reactivity eventually develops in many smokers after prolonged exposure to tobacco. Hence more specific mechanisms enhancing bronchial reactivity may be superimposed on the background influence of altered airway geometry in smokers. A prospective study of changes in baseline FEV, and in PC20 in an individual will be required to permit quantification of the precise role of altered geometry.
Another way in which diminished airway calibre might influence bronchial reactivity is by altering the site of deposition of histamine inhaled into the lungs. By alteration of the mode of administration of the aerosol, histamine can be preferentially deposited on central rather than peripheral airways, and then appears to be more effective in reducing FEV,. 33 This could be because irritant receptors are more numerous centrally34 or because the FEV, may Bronchial reactivity to inhaled histamine and rate of decline in FEV, in smokers and ex-smokers be more sensitive to changes in central than in peripheral airways. In relatively advanced airflow obstruction aerosol deposition on central airways is increased,35 but this change in deposition is consistently found only when FEV, falls below about 60% of the predicted value,36 and we found enhanced reactivity in men whose FEV, was higher than this. Moreover, recent studies36-38 do not support the earlier contention that penetration of aerosol into the lungs is reduced even in symptomless smokers,39 and emphasise the considerable overlap between normal smokers and non-smokers in aerosol penetration. Hence the increased reactivity in our smokers is more likely to have resulted from the direct influence of diminished airway calibre than from any consequent reduction ir. the depth of penetration of inhaled histamine into the lungs.
The effects of reduced airway calibre in increasing reactivity would not be confined to smoking related disease but would also apply when airway narrowing was due to asthma or cystic fibrosis. A more specific effect of smoking, which is apparent within a few days of the starting of smoking,40 is to increase airway permeability, as shown by the rapid removal from the lungs of radiolabelled diethylenetriamine penta-acetic acid (DTPA) aerosol.4' 42 Increased permeability of the airways, however, cannot account entirely for the abnormal bronchial reactivity of smokers. We found abnormal reactivity in only a minority of smokers, but virtually all have increased permeability. This disparity is even more evident in younger smokers, in whom the reactivity of the airway to histamine bears no relation to its permeability to DTPA.43 Furthermore, the change in permeability reverses within weeks of cessation of smoking,4244 but enhanced bronchial reactivity was evident in some of our ex-smokers years after stopping smoking.
A further possibility is that bronchial reactivity might be increased during the smoking years by an immunological mechanism. As discussed elsewhere,'0 there are increases which are probably acquired in blood eosinophils in smokers and a small rise in total serum IgE in smokers with negative skin test responses. Neither blood eosinophil count nor total IgE, however, was related to increased reactivity or annual rate of decline in FEVI in smokers.
Conceivably, smoking could amplify the effect of pre-existing but subclinical allergy; on the other hand, we did not find an increased prevalence of positive skin test responses in smokers.'0 Chan Yeung and Dy Buncio45 have recently described an inverse relation between the peripheral blood leucocyte count and FEV,. The association was present irrespective of smoking habit, though heavier smokers had higher white cell counts. If the leucocyte count were an important independent determinant of FEV,, we should have expected to find that it was related not only to baseline FEV, but also to annual AFEVI/ht3; but no such association was apparent in our smokers, ex-smokers, or nonsmokers.
In summary, our finding of increased bronchial reactivity in smokers with acclerated annual decline of FEV, and reduced baseline FEV, is compatible with the "Dutch hypothesis," but increased reactivity may follow rather than precede the onset of smoking. The evidence for an associated allergic factor was relatively weak. While the hypothesis cannot explain all the features of smoking related airflow obstruction-for instance, the predominance of men, the association with poor socioeconomic status, and, most strikingly, the almost inevitable development of emphysema when airflow obstruction is severe46-further studies are required to investigate the origins of the increased bronchial reactivity.
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